Kenvue CEO Discusses Growth Outlook After J&J Unit Jumps 20% in Market Debut
Johnson & Johnson's consumer-health unit Kenvue made its debut on the New York Stock Exchange and jumped about 20% on Thursday. Thibaut Mongon, CEO of Kenvue, joined Cheddar News to discuss business growth goals and what lies ahead for its well-known pipeline of products, including Band-Aid, Neutrogena, Tylenol, among others.
Stocks fell at the open Tuesday as the 10-year Treasury yield spiked following retail sales data and bank earnings, raising concerns over more rate hikes. Investors are also keeping an eye on tensions in the Middle East and its potential effect on global markets.
Rite Aid has filed for bankruptcy protection and plans to sell part of its business as it attempts to restructure while dealing with losses and opioid-related lawsuits.
